<DOC>
	<DOCNO>NCT01929239</DOCNO>
	<brief_summary>This Phase Ib Pilot study anti-PSMA designer T cell metastatic prostate cancer . Subjects receive escalate dos T cell , either low moderate dose Interleukin 2 . The T cell collect pheresis genetically modify , give one time infusion .</brief_summary>
	<brief_title>Trial Anti-PSMA Designer T Cells Advanced Prostate Cancer After Non-Myeloablative Conditioning</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>5.2.1 Patient histologically confirm diagnosis prostate cancer . 5.2.2 Patient rise serum PSA , ( prostate specific antigen ) . 5.2.3 Tumor hormone refractory , document rise PSA two value separate time . Patients may enroll rise PSA withdrawal androgen therapy enrol onto protocol androgen ablation therapy , must remain androgen therapy duration protocol . Patients may enroll tumor hormone refractory refuse hormone therapy time , understand hormone therapy standard treatment disease stage . 5.2.4 Patient must least 18 year age . 5.2.5 Patient able understand sign inform consent . 5.2.6 Patient life expectancy great four month . 5.2.7 Patient performance status 0 1 . ( http : //www.ecog.org/general/perf_stat.html ) . 5.2.8 Patient adequate organ function define : 5.2.8.1 ANC 1.0 , platelet 50,000 , Hgb 8.0 ; patient may transfuse achieve Hgb 8.0 satisfy enrollment criterion , otherwise indicate symptom Hgb &gt; 8.0 . 5.2.8.2 Creatinine 1.5mg/dl creatinine clearance 60cc/min . 5.2.8.3 Direct bilirubin 1.5 mg/dl . 5.2.8.4 No evidence congestive heart failure , symptom coronary artery disease , serious cardiac arrhythmia , include atrial fibrillation/atrial flutter , evidence prior myocardial infarction history EKG . A normal cardiac stress test inducible ischemia arrhythmia within 12 week prior enrollment patient 50 year old abnormal EKG history symptom suggestive cardiac disease . 5.2.8.5 No serious , symptomatic obstructive emphysemaÂ¬tous lung disease , asthma require intravenous medication within past 12 month ; serious lung disease associate dyspnea normal activity level ( grade III ) rest ( grade IV ) , due cause ( include cancer metastases pleural effusion ) . The patient ineligible PFTs show FEV1 &lt; 1.3 liter DLCO &lt; 50 % within 12 week study entry . For patient enrol cohort IIA , IIB , III : 5.2.9 Patients disease bone site ( ) biopsyable tumor ( radiologically externallyaccessible site ) , willing undergo biopsy specify 6.3.6 . For group , patient &gt; 5 lesion bone scan positive lesion prefer increase yield blind bone marrow biopsy . Alternatively , patient bone extraskeletal lesion may biopsied CT guide open procedure . 5.3.1 Patients serious unstable renal , hepatic , pulmonary , cardiovascular , endocrine , rheumatologic , allergic disease base history , physical exam laboratory test exclude , outline section 5.2.9 . 5.3.2 Patients active clinical disease cause CMV , hepatitis B C , HIV tuberculosis exclude study . 5.3.3 Patients cytotoxic and/or radiation therapy four week prior entry initiated antiandrogen therapy less six week prior entry exclude . 5.3.4 Patients concurrent malignancy exclude . 5.3.5 Patients require systemic steroid exclude . 5.3.6 Patients prior investigational therapy within 4 week prior entry exclude . 5.3.7 Patients previously expose mouse antibody exclude , unless prove ELISA negative baseline human antimouse antibody ( HAMA ) titer . 5.3.8 Patients irradiation whole pelvis 25 % total marrow exclude .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>